Based on Types of Lymphoma / CLL
|
In the News
.gif) |
Study of interest posted
below: MPDL3280A - pd-L1 antibody
in Hematologic Malignancies -
http://1.usa.gov/16oO4dH
Many locations
in the US and
Europe.
PD-L1 is a ligand of PD-1 ... communication
receptors that allow tumor cells to put t-cells
to sleep. Blocking these receptors appears to
allow t-cells to wake up - activate - and kill
tumor cells. This has been studied mainly in
advanced solid tumors with exciting results.
Background on mechanism:
PAL |
.gif) |
New study of interest
posted below:
Brentuximab Vedotin WITH Bendamustine in
Patients With relapsed Hodgkin Lymphoma -
ClinicalTrials.gov
http://1.usa.gov/163W57P
Key eligibility: Excluded if Received
prior salvage therapy, including radiotherapy
Many locations in US, both coasts
|
.gif) |
New study of interest
posted below:
Ibrutinib With R-CHOP for CD20 positive
lymphoma
http://1.usa.gov/13D0tbE
Multiple study locations:
US: NY, TN, TX; France
|
.gif) |
New study of interest
posted below:
ABT-199 WITH
Bendamustine/Rituximab (BR) for
Relapsed or Refractory NHL
http://1.usa.gov/10StJaU
|
.gif) |
Donor T Cells
After Donor Stem Cell Transplant
in Treating
Patients With Hematologic Malignancies -
ClinicalTrials.gov
http://1.usa.gov/10uGGNT
|
RELATED ITEMS
.gif) |
|
.gif) |
News Medical: Phase III study using ibrutinib in CLL patients
completed
http://bit.ly/ZK8qZy
|
.gif) |
Dr. Sharman's CLL &
Lymphoma Blog: New Study Available for CLL/NHL
http://bit.ly/17BoHUi
|
.gif) |
ClinicalTrials.gov:
Feasibility of Assessing Lymphoma
Response
to
Precise Local Injection of Candidate
Chemotherapy Agents
-
ClinicalTrials.gov
http://1.usa.gov/Ztul7n
|
.gif) |
Weill Cornell: New
clinical trial: Ibrutinib in Refractory
Follicular Lymphoma
http://bit.ly/14AqMEc
Ibrutinib (an
oral btk-inhibitor) in
Refractory Follicular Lymphoma
|
|
|
|
CLL / SLL
relapsed OR previously untreated,
OR no
prior transplant
Location:
Multiple centers in many regions of US and abroad. Open
study above for details.
Clicks as of
11/20/13: New Today:
>
Contacts not provided.
To contact the sponsor for study locations:
http://www.clinicalconnection.com/ContactUs.aspx
(completing a form)
Please refer to this study by its ClinicalTrials.gov
identifier: NCT01682616
|
CLL / SLL
with current need to treat, over 65 years of age
OR
having 17p or p53 risk factors
Location:
Multiple centers in many regions of US and abroad. Open
study
above
for details.
Clicks as of
1/20/13:
40 Today: >
|
CLL / SLL
previously untreated OR relapsed,
need to treat,
no
transformation
* No
Longer Recruiting
Clicks as of
1/20/13:
61 Today:
>
|
CLL / SLL
relapsed <24 months since last
treatment
with current
need to treat, not eligible for chemo
Location:
Multiple centers in many regions of US and abroad. Open
study above for details.
Clicks as of
1/20/13:
31
Today: >
|
CLL / SLL
relapsed less than 36 months after
last treatment
with current
need to treat
Location:
Multiple centers in many regions of US and abroad. Open
study
above
for details.
Clicks as of
1/20/13:
9
Today: >
|
CLL / SLL
previously untreated, -
elderly (over 65 years)
Location:
Multiple centers in many regions of US and abroad. Open
study
above
for details.
Clicks as of
1/20/13:
38
Today: >
|
|
Return to To |
|
|
|
Central Nervous System (CNS) Lymphoma |
|
CNS
Lymphoma - primary
previously untreated
Location:
Alliance (CALGB) study: multiple centers in many regions
of US. Open study
above
for details.
Clicks as of
1/20/13:
6
Today:
>
|
|
CNS / intraocular
Lymphoma
relapsed or refractory
Location:
University of California, San Francisco. Open study
above for
details.
Clicks as of
1/20/13:
30 Today: >
|
|
Return to Top |
Follicular lymphoma
|
Follicular
lymphoma
advanced stage, previously untreated
Bexxar with Low-Dose chemotherapy
Location:
University of Michigan Cancer Center Open study above for
details.
Clicks as of
1/20/13:
32 Today:
>
|
Follicular
lymphoma
relapsed -
responded to prior Rituxan-based
treatment
* Not yet recruiting.
Open study above for details.
Location:
Alliance (CALGB) study: will open in multiple centers in
many regions of US. Open study for details.
Clicks as of
1/20/13:
50 Today:
>
|
Follicular lymphoma
grade 1-3a,
stage II-IV -
previously untreated, current
need to treat
Location:
Multiple centers in many regions of US. Open study above for
details.
Clicks as of 3/31/13:
fixed Today: >
|
Follicular
lymphoma
stage I or II, grade I or II -
previously untreated
Location:
MD Anderson Cancer Center Houston, Texas, United States,
77030
* Not yet recruiting.
Open study above for details.
Clicks as of
1/20/13:
16 Today:
>
|
Follicular
lymphoma
relapsed, responsive to last Rituxan
Location:
Alliance (CALGB) study: open in multiple centers in many
regions of US. Open study above for details.
Clicks as of
1/20/13:
103
Today:
>
|
Follicular
lymphoma
previously untreated, with need to treat
Key Eligibility: Achieved a response to induction treatment with either
R-CHOP
(6 cycles of R-CHOP21 or R-CHOP14), R-CVP (6
cycles), or R-B (4 to 6 cycles).
Must have
completed all doses of the induction treatment,
except
for the modifications allowed in the protocol.
Clicks as of
1/20/13: 16
Today:
>
|
Follicular lymphoma
previously
untreated, measurable disease but not bulky
Location:
NY City - Weil Medical College. Open study above for
details.
Update on eligibility by word of
mouth: recurrent FL may be eligible
Study drug
reports
Clicks as of
1/20/13:
33 Today:
>
|
|
Return to Top
|
Hodgkin Lymphoma
|
Hodgkin
Lymphoma
untreated stage
I/II,
non-bulky
Study drugs:
ABVD
chemotherapy x2 then based on PET: ABVD x2 OR BEACOPP x2 then
IFRT (radiotherapy)
Clicks as of
1/20/13:
16
Today:
>
|
Hodgkin
Lymphoma
cd-30 positive -
relapsed or refractory
Clicks as of
1/20/13:
75
Today:
>
|
Hodgkin
Lymphoma
stage II-IV, previously untreated
age 60
years or older
Clicks as of
1/20/13: 22 Today: >
|
Hodgkin
Lymphoma
relapsed or refractory, no prior salvage therapy
Brentuximab Vedotin WITH Bendamustine
Key eligibility:
Excluded if received
prior salvage therapy, including radiotherapy
Locations: many in US, both coasts
Clicks as of
6/10/13:
NEW
Today:
>
|
Hodgkin
Lymphoma
primary refractory OR relapsed
Radiolabeled
Monoclonal Antibody Therapy AND Combination Chemotherapy
BEFORE Stem Cell Transplant
No
study drug reports
Clicks as of
1/20/13: 38 Today: >
|
|
Return to Top
|
|
|
MCL
previously untreated,
over 60
years of age
Clicks as of
1/20/13: 8
Today: >
|
MCL
relapsed
progressed after last Velcade Therapy
Clicks as of
1/20/13:
19
Today:
>
|
MCL
previously untreated
OR did not achieve partial response after most
recent treatment
Ibrutinib (btk-inhibitor
/ PCI-32765)
Clicks as of
1/20/13:
25 Today:
>
|
MCL
relapsed - (not yet recruiting as of May 3)
Lenalidomide and Rituximab WITH or WITHOUT
Idelalisib (CAL101)
Rituximab is an
antibody that binds to cd20 - expressed on
mature b-cells - which activates the immune
system.
Lenalidomide is an immune modulating agent that
has activity in MCL as a single agent.
Idelalisib (CAL101) is an investigational agent
that targets a pathway that controls the b-cell
receptor.
Clicks as of
5/9/2013: NEW Today:
>
|
|
Return to Top |
Lymphoma - mixed types | GVHD
|
lymphoma,
b-cell
MCL, Low Grade NHL, DLBCL
relapsed and
refractory
|
b-cell
NHL OR CLL
cd-19 positive,
high-risk, refractory to chemotherapy
at least 2 prior
therapies
Location:
PA
Clicks as of
1/20/13: 136
Today: >
|
b-cell lymphoma
/ CLL (many types)
relapsed and refractory to chemotherapy
Location:
China
Clicks as of
1/20/13: NEW Today: >
|
b-cell aggressive lymphoma
relapsed and refractory,
high-risk, intermediate grade
Clicks as of
1/20/13: 8 Today: >
|
lymphoma
-
Hodgkins OR NHL
second or
subsequent relapsed after Stem cell Transplant
Clicks as of
1/20/13:
63 Today:
>
|
DLBCL or
transformed with CD79 Mutation
Eligibility:
relapsed DLBCL with
activating mutations in CD79.
DLBCL that arose from transformed
indolent lymphoma is allowed.
Location:
multiple centers
Related report:
Protein Kinase C
Inhibitor Sotrastaurin Selectively Inhibits CD79
Mutant DLBCL
aacrjournals.org
"We provide several lines
of evidence to show that the selective killing
of CD79 mutant ABC DLBCL cells by STN is due to
on-target PKC inhibition. "
|
lymphoma,
b or t-cell
Hodgkin AND NHL, relapsed,
NO CNS or active autoimmune disease
Location:
Multiple centers in many regions of US. Open
study for details
Clicks as of
1/20/13: 25 Today:
>
|
b-cell aggressive lymphoma
cd20-positive,
relapsed
Belinostat (HDAC inhibitor) WITH Zevalin
Key eligibility:
CD20 positive DLBCL, MCL, high grade-B-cell or
anaplastic large B cell NHL;
AND bone marrow =< 20%
involvement; first relapse eligible if not a candidate
for transplant.
Report: Interim
Results of a Phase 1 Trial of An Oral Histone
Deacetylase
Inhibitor Belinostat In Patients with
Lymphoid Malignancies (b or t-cell)
http://ash.confex.com
Clicks as of
1/20/13: 33
Today: >
|
lymphoma -
cd30 positive
Hodgkin OR anaplastic large-cell
relapsed -
failed or declined transplant
Key eligibility:
relapsed HL or ALCL; for
HL, failed or declined stem cell transplant
Clicks as of
1/20/13:
63
Today:
>
|
b-cell, NHL /
CLL
relapsed or refractory
Clicks as of
1/20/13:
62
Today: >
|
b-cell NHL
low or high grade - including DLBCL,
relapsed and
refractory
Clicks as of 1/20/13:
21
Today:
>
|
lymphoma,
b-cell
MCL, Low Grade NHL, SLL/CLL),
Transformed, DLBCL/PMBCL, Hodgkin's Disease
relapsed and
refractory
Everolimus WITH Rituxan maintenance
AFTER High-dose Consolidative Therapy
Location:
Baltimore, Maryland, United States, 21231 Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins.
Open
study for details:
Clicks as of 1/20/13:
New
Today:
>
|
lymphoma,
relapsed and
refractory
Clicks as of 1/20/13:
New
Today:
>
|
b-cell NHL
- DLBCL
indolent or aggressive cd20
positive lymphoma, no prior combination chemo
Ibrutinib WITH R-CHOP
Multiple study locations:
US: NY, TN, TX; France
Clicks as of
1/20/13:
NEW Today: >
|
b-cell NHL
- DLBCL
indolent NHL, MCL,
relapsed
Location:
Ohio
Clicks as of
1/20/13:
93 Today: >
|
b-cell
NHL, many types, indolent
relapsed,
not transformed
Idelalisib (GS-1101 / CAL101) WITH
Rituxan
Clicks as of
6/01/13:
New
Today:
>
|
b-cell
NHL, indolent
relapsed, not transformed
Idelalisib (GS-1101 / CAL101) WITH Bendamustine +
Rituxan
Clicks as of
6/01/13:
New
Today:
>
|
b-cell
NHL, indolent
FL, CLL, LPL, MZL -
at least 2 prior therapies,
not transformed
Idelalisib (GS01101 / CAL-101)
Clicks as of
1/20/13:
16
Today:
>
|
Hematologic Malignancies - lymphomas
no risk of autoimmune disease[ no
prior transplant, or CNS involvement
MPDL3280A - PD-L1 antibody (immune-checkpoint blockade)
Many locations in
the US and Europe.
PD-L1 is a ligand of PD-1 ... communication receptors
that allow tumor cells to put t-cells to sleep. Blocking
these receptors appears to allow t-cells to wake up -
activate - and kill tumor cells. This has been studied
mainly in advanced solid tumors with exciting results.
Background on mechanism:
PAL
Clicks as of
1/20/13:
NEW
Today:
> |
b-cell
lymphoma cd20
positive
relapsed or refractory
Clicks as of
1/20/13:
53 Today:
>
|
b-cell
lymphoma
including MCL and transformed -
poor
risk, relapsed or refractory
Zevalin WITH
Rituxan-BEAM Chemotherapy, THEN Autologous Stem Cell
Transplant
Clicks as of
1/20/13:
3 Today:
>
|
Other Indications
|
Graft versus
Host Disease
acute,
steroid-refractory
Brentuximab Vedotin for Steroid Refractory GvHD
Clicks as of
1/20/13: 11 Today:
>
|
|
Return to Top |
T-cell lymphoma, mixed types
|
T-cell
lymphoma
Peripheral type,
relapsed or
refractory
Clicks as of
1/20/13: 10
Today:
>
|
T-cell lymphoma
cutaneous (CTCL)
Early-Stage (IA-IIA),
relapse after
1 or more treatments
Clicks as of
1/20/13:
8 Today:
>
|
T-cell lymphoma
PTCL and
other aggressive types,
previously untreated
Question based on a
recent report:
Does SAHA inhibit the efficacy
of chemotherapy when given in combination?
Clicks as of
1/20/13: 16 Today: > |
|
Return to Top |
DLBCL (Diffuse Large B-Cell Lymphoma)
|
DLBCL
previously untreated
Location:
Weill Cornell Medical College New York, New York, United
States. Open study above for details.
Study drug reports
Clicks as of
1/20/13: 2
Today: >
|
DLBCL
including transformed
relapsed or
refractory AND not eligible for transplant
Clicks as of
1/20/13:
22
Today: >
|
DLBCL
relapsed or refractory
Clicks as of 1/20/13:
20 Today:
>
|
DLBCL
previously untreated
Location:
Multiple centers in many regions of US. Open
study above for details.
Study drug reports
Clicks as of
1/20/13: New
Today: >
|
DLBCL
including subtypes
previously untreated
Clicks as of
1/20/13: 123
Today:
>
|
|
Return to Top |